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Abstract Background: A considerable number of
patients admitted to the intensive care unit (ICU) die
following withdrawal of mechanical ventilation. After
discontinuation of ventilation without proper preparation,
excessive respiratory secretion is common, resulting in a
‘death rattle’. Post-extubation stridor can give rise to the
relatives’ perception that the patient is choking and
suffering. Existing protocols lack adequate anticipatory
preparation to respond to all distressing symptoms.
Methods: We analyzed existing treatment strategies in
distressing symptoms after discontinuation of mechanical
ventilation. Conclusion: The actual period of
discontinuation of mechanical ventilation can be very
short, but thoughtful anticipation of distressing symptoms
takes time. There is an ethical responsibility to anticipate
and treat (iatrogenic) symptoms such as pain, dyspnea-
associated respiratory distress, anxiety, delirium, post-
extubation stridor, and excessive broncho-pulmonary
secretions. This makes withdrawal of mechanical
ventilation in ICU patients a thoughtful process, taking
palliative actions instead of fast terminal actions. We
developed a flowchart covering all possible distressing
symptoms that can occur after withdrawal of mechanical
ventilation and extubation. We recommend a two-phase
process. Six hours before extubation, enteral feeding
should be stopped and parenteral fluids reduced,
overhydrated patients should be dehydrated with
furosemide, administration of sedatives (for distress)
and opioids (for pain and/or dyspnea) should be
continued or started and methylprednisolone should be
given in anticipation of stridor after extubation. Thirty
minutes before extubation, Butylscopolamine should
be given and methylprednisolone repeated. After this
the patient should be extubated to secure a dying process
as natural as possible with the lowest burden due to
distress.
Introduction
A considerable number of patients admitted to the
intensive care unit (ICU) die following withdrawal of
mechanical ventilation [1–9]. Comfort of patients and
relatives is essential in the withdrawal process [10].
Withdrawal of mechanical ventilation in patients beyond
hope is often described as ‘terminal weaning’ [2, 3], a
contradictory word that should be avoided [11]. Some
ICU patients request discontinuation of ventilation
themselves [12, 13], but most are unconscious. The
decision is usually made by the physician and is based on
a lack of correlation between the therapeutic effort and
its effect [5]. Discontinuation of ventilation should be a
process, especially in patients in which it can be predicted
that spontaneous respiratory activity will be sustained
for a significant period of time, requiring great prepara-
tion for adequate treatment of distressing symptoms. Few
ICU scenes evoke greater consternation in relatives
than the sight of a loved-one dying in apparent respira-
tory distress, gasping to catch adequate breath before
death.
In one study, 33% of intensivists preferred a ‘slower
process of terminal withdrawal of ventilation’ compared
to 13% who preferred ‘rapid extubation’ [14]. Existing
protocols are unsatisfactory due to lack of adequate
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preparation for treatment of all distressing symptoms
[15, 16]. Patients are rarely extubated before dying
[46]. Following ventilation discontinuation without
proper anticipatory preparation, excessive respiratory
secretion is not uncommon, resulting in a ‘death rattle’
[17]. Post-extubation stridor can give rise to relatives’
perception that the patient is choking and suffering while
dying.
Care before withdrawal of mechanical ventilation
should include:
1. Anticipation of pain, dyspnea associated respiratory
distress (DARD), and terminal restlessness and treat-
ment with adequate administration of opioids and
sedatives.
2. Treatment of distressing symptoms when they occur
despite anticipation.
3. Prevention of distressing symptoms such as excessive
broncho-pulmonary secretion, ‘death rattle’, and post-
extubation stridor by means of timely withdrawal of
the administration of parenteral fluids, pharmacolog-
ical treatment of iatrogenic overhydration, and
administration of methylprednisolone and anticholin-
ergic agents.
Here we provide practical and ethical arguments
regarding the need for anticipation of these symptoms.
Administration of opioids
Administration of opioids, sufficient to counteract pain
and/or DARD should be established before ventilator
withdrawal. Since many patients already receive benzo-
diazepines/opioids before the decision to withdraw
treatment, the strategy is based on the existing dose and
the prediction of the degree of DARD after withdrawal
[14]. There is always the risk of under-medicating for
pain, based on the assumption that ‘no-pain’ is associated
with neuromuscular blockade during therapeutic ventila-
tion [18, 19]. Lying in bed, sedated and with severe organ
failure, can cause severe pain in muscles and ligaments,
especially in elderly patients. This is the main reason for
the administration of opioids for pain in end-of-life care
on the ICU. Sometimes opiods are proposed for use in
‘sedation’ [20]. Opioids are inadequate for sedation
because they simply do not induce and maintain sleep
[21], but can induce hallucinations, delirium, and rest-
lessness [22]. One of the reasons to sedate a terminal
patient is to relieve terminal stress. The dying ‘organism’
experiences stress due to organ and systemic failure,
leading to irreversible destruction of homeostasis and
physical death. An increase in endogenous cortisol is
presumed to be a protective reflex against these fatal
threats. It was hypothesized that if the extent of the
terminal stress reaction was high, high-dose morphine
administration would suppress a rise in cortisol levels.
However, results indicate that cortisol levels are not
suppressed by high-dose morphine [23]. Thus, adminis-
tering morphine to moribund patients for relief of
terminal stress is not effective. The only valid reason for
morphine administration is the relief from (suspected)
pain or the prevention and treatment of DARD, which is
an observable corollary to subjective dyspnea. For
patients and relatives, the sensation of breathlessness is
one of the most terrifying symptoms during the dying
process. Relatives fear the patient is undergoing excessive
suffering due to suffocation. Opioids are often recom-
mended agents for managing DARD [9, 24–26]. Several
mechanisms may be responsible for the observed effects.
Ventilatory insufficiency and failure at the end of life
results from a number of causes including reduced
respiratory neuromuscular capacity, increased load by
airway obstruction, diminished lung and chest wall
compliance, and suppression of the cerebral ventilatory
drive in response to high CO2 levels. Several intercurrent
stresses such as anxiety, fever, bronchoconstriction, or
stridor may increase fatigue by further increasing drive,
effort, and load. Augmented drive by increase in venti-
latory effort can result in fatigue, which is clinically
significant as shallow breathing occurs, leading to death
[26]. Morphine reduces the work load of breathing,
thereby protecting against premature death from fatigue
[26].
Unfortunately, palliative administration of opioids is
perceived as hastening of death [27]. Several studies have
shown, however, that it does not effect survival in palli-
ative [28–30] and ICU patients [2, 26, 31–33]. Doses
exceeding the required amount necessary to achieve the
desired effect of symptom relief should not be used. Much
attention is given to physicians’ intentions, but distin-
guishing between intent to provide palliative comfort or
to hasten death is an impossible task. Indirect or hidden
intentions cannot be completely determined. The admin-
istered dose and choice of medication in the individual
patient, rather than intent, should be the determinant as to
whether the physician is acting in accordance with normal
standards. The often-mentioned risk of ‘serious respira-
tory depression’ is very rare [21, 34]. Among 1,524 post-
operative patients treated with systemic or neuraxial
morphine, a respiratory rate of less than 10 breaths/min
was recorded in only 18 (1.2%) patients [35]. The term
‘respiratory depression’ has no clear definition [34], but in
most cases it refers to low respiratory rate (\10 breaths/
min), but are of no concern to dying patients, or at times,
even desired. Death of an ICU patient is usually related to
fatigue and dysfunction in multiple organs after with-
drawal of ventilatory support and is not due to the
administration of opioids.
Fentanyl is a potent analgesic [36], but should not be
used for the prevention or treatment of DARD because it
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can increase muscle tone, leading to chest rigidity. This
can induce breathlessness instead of treating it, especially
in cachectic patients with weak muscles [37].
We recommend that morphine be started in order to
prevent DARD, and that fentanyl be continued for pain, if
that drug is already being used. Morphine could be started
in patients with no or low tolerance, as an intravenous
dose of 0.1 mg/kg. Individuals with high tolerance require
larger dosages. The pharmacokinetics of intravenous
morphine show a peak effect within 30 min and this effect
generally lasts for 1–2 h [44].
Palliative sedation
Palliative sedation is defined as deliberately inducing and
maintaining deep sleep for the relief of intractable phys-
ical and mental symptoms in the last hours or days of life.
In the ICU, palliative sedation is administered continu-
ously until death. ICU patients, particularly those
requiring mechanical ventilation, usually are already
sedated such that they can tolerate ventilation and ICU-
associated noxious stimuli. One of the goals of sedation
before and after withdrawal of ventilation is anxiolysis. In
ICU patients who are dying following withdrawal of
ventilation, death occurs rapidly, even if they are not
sedated. Therapeutic sedation thus becomes palliative
sedation. Decreased consciousness is a means of achiev-
ing symptom relief in patients who are suspected to be
dying or whose relatives are witnessing distressing
symptoms. Seizures, tremors, confusion, anxiety, agita-
tion, and hallucinations can also occur after
benzodiazepine withdrawal. This is one of the reasons
sedation should never be stopped at the end of life. There
is also some evidence suggesting that sedatives, espe-
cially lorazepam, are independently associated with the
development of delirium [38]. For this reason, we avoid
the use of lorazepam as a sedative for symptom control. In
some situations, midazolam can be effective when given
as adjunct therapy to morphine in order to alleviate
dyspnea [39]. There is no evidence that the use of ben-
zodiazepines to treat discomfort after withdrawal of
mechanical ventilation hastens death in palliative [40] or
ICU patients [26, 31, 33]. Respiratory rates do not
decrease to fatal levels when patients are given palliative
sedation [35].
We recommend midazolam or propofol (Fig. 1).
Midazolam has a rapid onset of action and is easily
titrated. In patients with prolonged mechanical ventila-
tion, sedation is problematic because tolerance can be an
especially difficult problem in the palliative phase [41].
Propofol also has an antiemetic effect, but can be asso-
ciated with severe myalgia and also cannot be given
subcutaneously, which could be a problem in some
cases.
Neuromuscular blocking
Some physicians choose to continue (or initiate) neuro-
muscular blocking agents after withdrawal of ventilation,
while others believe that this constitutes deliberate ter-
mination of life and is therefore unethical [42]. One
earlier study reports continuation of neuromuscular
blocking in 9% of 33 patients [31]. In end-of-life care, in
almost all patients, comfort can be achieved by adequate
dosing of opioids and benzodiazepines or barbiturates
without the use of neuromuscular blocking agents, which
can and should be reversed within a short period. Neu-
romuscular blocking agents produce only the appearance
of comfort [19] and deliberately terminate life as effect of
the iatrogenic neuromuscular blockage in the absence of
mechanical ventilation in patients. The agents are often
continued or administered for prevention of gasping
during the dying process. The half-life of these agents can
often be hours and is frequently longer in patients with
organ failure.
We believe there is no place for neuromuscular
blocking agents in the treatment of dying patients after
withdrawal of ventilation. Any existing therapeutic
rationale is lost in the process of treatment withdrawal. It
is only in patients who have received the agents in large
doses, where neuromuscular function can only be par-
tially restored due to organ failure and extreme fatigue,
that an ethical challenge exists. Restoration of neuro-
muscular function can delay the actual withdrawal of
mechanical ventilation beyond a point that is ethically
defendable, producing more harm than benefit. These
patients will not survive after withdrawal of ventilation
and will die within minutes to hours, even without the
influence of neuromuscular paralysis. The activity of any
residual neuromuscular blocking agents can then not be
seen as deliberate termination of life.
Anticipation of excessive secretion
Excessive broncho-pulmonary secretion is common in
ICU patients after withdrawal of prolonged ventilation
and can give rise to the development of a death rattle,
which is often distressing for relatives to witness. In ICU
patients, iatrogenic overhydration and prolonged
mechanical ventilation are common causes of this prob-
lem. Withdrawal of mechanical ventilation should always
be preceded by withdrawal of all artificial hydration and
feeding. Furosemide should be given in cases of iatro-
genic overhydration to reduce the risk of excessive
broncho-pulmonary secretion and death rattle and to
prevent airway obstruction and bronchospasm [43, 44].
The noise produced by oscillatory movements of
secretions in the oropharynx, hypopharynx, and trachea in
terminal patients is described as a ‘death rattle’. Dying
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patients are usually too weak to expectorate or swallow
the migrating secretions. Sputum usually only accumu-
lates in these areas if there is significant impairment of the
cough reflex, as in coma or near death. Death rattle is
commonly reported in patients with neurological and
pulmonary conditions during the last 48 h of life, with a
prevalence of 40–50% [17]. Observational studies report
41–92% and larger prospective studies report an inci-
dence of 44–56%. The presence of a death rattle precedes
death within 48 h in almost 75% of patients. Most patients
appear to be unaware of their rattling respiration due to
altered consciousness, and as long as they do not suffer,
there is no ethical demand to treat it from the perspective
of the patient. Only a few palliative care nurses felt that
death rattle distressed the patient [45]. The primary aim of
preventing or treating the noisy breathing is to reduce the
distress of relatives of the patients and caregivers. We
recommend administration of 20 mg Butylscopolamine or
0.4 mg Hyoscine hydrobromide 30 min, before extubation
to prevent a death rattle.
Extubation and post-extubation stridor
The decision to remove the endotracheal tube should be a
secondary decision following discontinuation of ventila-
tion. Extubation in the face of death (often called
Decision to withdraw mechanical ventilation and subsequent removal of 
endotracheal tube based on medical criteria that further treatment is futile or 
disproportionate, or on patient’s request to withdraw mechanical ventilation. The
patient is allowed to die
Inform the relatives about the decision and the 
consequences of the decision 
Is the patient competent? Yes
No
Inform the patient and relatives 
about the decision and the 
consequences of the decision 
6 hours before extubation 
Stop enteral (tube)feeding and reduce parental 
fluids to a maximum of 25cc NaCl 0,9%/hr (this
reduces the risk on the occurrence of ‘death rattle’)
Is the patient ‘overhydrated’, administer 40-80 
Mgr Furosemide IV as a bolus.  In case of 
insufficient effect after 30 min, administer 250-
500 Mgr Furosemide IV within one hour. 
For prevention of postextubation stridor: 
administer 100 Mgr Methylprednisolon IV
If the patient already receives Midazolam or 
Propofol for sedation and/or morphine or 
Fentanyl for analgesia or respiartory symptoms, 
and this is considered as adequate, continue this.  
If not sedated or receiving opioids, start with: 
1. Midazolam, titrating till adequate sedation 
(0,1-0,3 mg/kgr) IV or Propofol 20-50 Mgr 
bolus, titrate till adequate sedation with 10 
Mgr/15 minutes (for sedation) 
2. Morphine 0,1 Mgr/kgr IV (for pain and/or 
dyspnea 
Reduce FiO2 till 21%, reduce PEEP to 0 cm-
H2O, set ventilator to pressure support 
Observe the patient and modify sedation and/or effect of opioids on pain and/or 
dyspnea till adequate effect.  
Hypoxia, hypotension or low O2-satuartion form no reason to change policy. 
30 minutes before extubation 
1. Administer 20 Mgr Butylscopolamine IV, or 0,4 Mgr Hyoscine hydrobromide SC, continue with 1,2 Mgr 
Hyoscine hydrobromide/ 24 hrs (for prevention of death rattle after removal of endotracheal tube). 
2. Administer again 100 Mgr Methylprednisolone IV (additional dose for prevention of stridor) 
Place the patient on a T-piece with humified air.  Remove endotracheal tube. 
Do not administer oxygen. 
Fig. 1 Flow chart for
withdrawal of mechanical
ventilation
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‘terminal extubation’) is the end of curative interventions
for life support and symbolizes the start of passage to the
end of life [46]. Post-extubation stridor is a potential
source of distress, especially for the relatives and care-
givers. The patient’s appearance during post-extubation
stridor is very disconcerting. Multi-center studies in
Europe show that extubation preceding death is the least-
used treatment, used only in 6–9% of cases, during dis-
continuation of ventilation [47, 48]. Two-thirds of French
caregivers felt that extubation should never be considered
because it might worsen distress and may have a causal
association with death. Fartoukh et al. [46] stated that the
negative association with extubation stems from the fact
that the family may interpret the ensuing noisy respiration
or labored breaths as discomfort. They recommend nasal
oxygen therapy immediately after extubation and in the
case of dyspnea, corticosteroid treatment with a nebulizer.
Increased sedation and analgesia were given in the case of
discomfort (stridor and asphyxia) and scopolamine was
given in accordance with the amount of respiratory
secretions.
We recommend non-removal of the endotracheal tube
only in exceptional cases because we believe post-extu-
bation stridor and death rattle can be preempted by
administering an intravenous injection of a single (or up to
4/day) dose of 100 mg of methylprednisolone at least 6 h
before extubation [49]. Studies found that after a single
dose of 100 mg of methylprednisolone, 88% of the patients
showed no stridor and 93% showed no stridor after four
doses. Stridor is the iatrogenic result of endotracheal
intubation, which should be prevented and treated when it
is distressing for the patient or their relatives. Gasping,
however, is something that cannot be treated and in con-
trast with post-extubation stridor, is a normal sign of
dying. Hypoxia serves as a ‘natural sedative’ at the end of
life. For this reason we do object to routine administration
of oxygen after extubation. This should be explained to the
relatives.
Relatives
Before mechanical ventilation is withdrawn, the ICU staff
should discuss with the relatives of the patient the
intended withdrawal procedure, prepare for distressing
symptoms, and the expected chance of survival [6]. The
perceptions the relatives have regarding suffering and
distress of the patient are important determinants for
palliative care after withdrawal of life support. Explana-
tion of the possible symptoms and of measures to
counteract those symptoms may allow them to rest easier
and reduce anxiety. ICU nurses prepare the relatives of
patients mostly by describing physical sensations and
symptoms [50]. Some patients will not die within min-
utes or hours after withdrawal of mechanical ventilation.
Some will even survive the ICU [5]. In our experi-
ence, most often, this concerns patients with severe
cerebral catastrophes, but with intact brainstem and
other organ functions. Physicians should be aware of
this when informing the relatives about prognosis of
survival.
Recommended process
For relatives, it is paramount that they see that their loved
one die without significant distress and that dying should
be as natural as can be. For this reason, we recommend a
two-phase, 6-h period for the process of withdrawal of
mechanical ventilation, taking the aforementioned aspects
into consideration (Fig. 1). In the first phase, lasting from
6 h to 30 min before actual withdrawal of mechanical
ventilation and removal of the endotracheal tube, the
focus is on sedation, analgesia, prevention of DARD,
post-extubation stridor, and excessive broncho-pulmonary
secretions as the result of overhydration. In the second
phase, 30 min before actual withdrawal of mechanical
ventilation and removal of the endotracheal tube, the
focus is on prevention of death rattle by means of medi-
cation. When this is followed, most patients will die
without significant distress and ‘naturally’ without tubes
and technology around the bed.
Conclusion
The actual phase of discontinuation of mechanical ven-
tilation can be very short, but thoughtful anticipation of
distressing symptoms takes more time. Given that the
patient has serious respiratory or ventilatory insufficiency,
multiple organ failure, extremely diseased lungs, or
severe neurological dysfunction, withdrawal of mechani-
cal ventilation and subsequent removal of an endotracheal
tube often induces or hastens death. These actions do not
kill the patient, but allow the patient’s disease to complete
its natural course. There is an ethical mandate to both
anticipate and treat (iatrogenic) induced symptoms such
as pain, DARD, anxiety, delirium, post-extubation stridor,
and excessive broncho-pulmonary secretions resulting
from overhydration. This makes the process of with-
drawal of mechanical ventilation in ICU patients a
thoughtful process, taking palliative actions instead of fast
terminal actions.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which
permits any noncommercial use, distribution, and reproduction in
any medium, provided the original author(s) and source are
credited.
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